IL17A and glioblastoma: The results showed that treatment with LY294002 significantly abolished the effect of IL‐17A on migration (**P < 0.01, ***P < 0.001) (Figure 4A and B) and invasion (**P < 0.01, ***P < 0.001) (Figure 4C and D) of U251 and U87 GBM cells.